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the thrombus size on ultrasound scan, following 
at least 28 days of rivaroxaban therapy and up to 
7 days from the onset of the thrombosis signs and 
symptoms (n = 11). The other patient group rep‑
resented subjects who reported persistent minor 
hemorrhagic complications, including easy bruis‑
ing or oral or nasal cavity bleeding while on rivar‑
oxaban despite a negative personal or family his‑
tory of a tendency for bleeding (n = 12).
The exclusion criteria were any acute illness, 
cancer, severe heart failure, creatinine clearance 
of less than 30 ml/min, impaired liver function 
(transaminases >2 × upper limit of normal), con‑
comitant medications interfering with the anti‑
coagulant effect of rivaroxaban, eg, amiodarone. 
All patients declared abstaining from the use of 
nonsteroidal anti‑inflammatory agents, including 
aspirin, within the preceding month.
Blood was drawn between 9 and 11 AM on 
an outpatient basis, 2 to 28 hours since the last 
dose of rivaroxaban. Hemoglobin, creatinine, 
PT, INR, and aPTT were determined by rou‑
tine laboratory techniques. Rivaroxaban con‑
centration was measured by the anti‑Xa chro‑
mogenic assay, Biophen DiXaI (Hyphen Biomed, 
Neuilly‑sur‑Oise, France) according to the man‑
ufacturer’s instructions.
Twenty apparently healthy subjects not receiv‑
ing rivaroxaban matched for age, sex, and renal 
function served as controls. In 13 controls, the 
results of the anti‑Xa chromogenic assay were 
negative, while in 7 individuals measurable lev‑
els were in the range of 1 to 23 µg/l.
All subjects gave informed consent to par‑
ticipate in the study. The study complied with 
the World Medical Association Declaration of 
Helsinki regarding ethical conduct of research 
involving human subjects.
Statistical analyses were performed with the 
SPSS 20.0 software. The Mann–Whitney test was 
used to compare differences between patients 
on rivaroxaban and controls, whereas the Krus‑
kal–Wallis test, followed by a test for multiple 
Introduction Rivaroxaban, a direct factor Xa in‑
hibitor, is approved for the prevention of stroke 
and systemic embolism in nonvalvular atrial fibril‑
lation as well as for the prevention and treatment 
of deep vein thrombosis (DVT) and pulmonary 
embolism.1‑4 In addition, rivaroxaban is currently 
accepted in combination with antiplatelet agents 
for the prevention of atherothrombotic events in 
patients with acute coronary syndromes. Rivarox‑
aban has predictable pharmacokinetics and phar‑
macodynamics and, in clinical practice, it is used 
at fixed doses without the need for routine coag‑
ulation monitoring. However, rivaroxaban is con‑
traindicated in patients with creatinine clearance 
of less than 30 ml/min. The peak plasma level is 
reached within 2 to 4 hours, and the half‑life is 
between 7 and 11 hours in patients with normal 
renal and hepatic function.1,2
Rivaroxaban can prolong prothrombin time 
(PT, with a subsequent increase in a calculated 
international normalized ratio [INR]) and ac‑
tivated partial thromboplastin time (aPTT), 
with weak associations of these parameters 
with plasma concentrations of the drug,5‑7 mea‑
sured directly by noncoagulation tests such as 
high‑performance liquid chromatography–tan‑
dem mass spectrometry.8
Monitoring of rivaroxaban concentrations may 
be useful in certain clinical situations such as ur‑
gent surgery, thromboembolic or bleeding compli‑
cations, or suspicion of an overdose.8‑10 The most 
commonly used assay for this purpose is a mod‑
ified antifactor‑Xa assay. We investigated rivar‑
oxaban concentrations in DVT patients who re‑
ported on‑treatment thrombosis progression or 
minor hemorrhagic complications.
Patients and methods We studied 23 patients 
(8 men and 15 women), aged 44 ±15 years, who 
received rivaroxaban (20 mg/d) following DVT 
within previous 1 to 6 months prior to blood col‑
lection. Patients were diagnosed with DVT pro‑
gression, defined as a symptomatic increase of 
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Patients with a history of thrombus progres‑
sion or hemorrhagic complications did not differ 
with regard to age, sex, renal function, aPTT, PT, 
INR, and drug concentrations. A univariate anal‑
ysis showed that the rivaroxaban concentration 
was associated only with the time since the last 
rivaroxaban dose to blood sampling (R2 = 0.63; 
P <0.001) and was correlated with PT both in pa‑
tients with thrombosis progression (R2 = 0.76; 
P=0.01) as well as in those with minor hemorrhag‑
ic complications (R2  = 0.84; P <0.001) (FIguRE 1A).
The pharmacokinetic curves of the relation‑
ship between the rivaroxaban concentration and 
the time since the last rivaroxaban dose and blood 
sampling overlapped in the 2 compared groups 
(FIguRE 1A). Between the 2 groups of thrombosis 
progression or minor hemorrhagic complications, 
rivaroxaban concentrations and prothrombin 
time did not differ significantly in the subgroups 
classified on the basis of the time since the last 
rivaroxaban dose to blood sampling (FIguRE 1B).
comparisons of mean ranks, was used to com‑
pare differences of single measurements in the 3 
groups. The association between 2 variables was 
assessed by the Spearman test. A multiple regres‑
sion analysis was applied to determine indepen‑
dent predictors of rivaroxaban concentrations. 
The analysis of covariance assuming homogene‑
ity of slopes including age, sex, renal function, 
and time since the last rivaroxaban dose to blood 
sampling as covariates was used to compare ri‑
varoxaban concentrations between patients with 
thrombus progression and minor bleeding com‑
plications. A 2‑sided P <0.05 was considered sta‑
tistically significant.
Results aPTT tended to be longer (medi‑
an, 28.9 vs. 27.1 s, P = 0.10) and PT was longer 
(12.3 vs. 11.4 s, P = 0.035) in patients on rivarox‑
aban compared with controls, which correspond‑
ed with the calculated INR values (1.09 vs. 1.0, P 
= 0.002, respectively).
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that may lead to thrombotic or bleeding events 
should be identified.
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The time since the last rivaroxaban dose to 
blood sampling was the only independent predic‑
tor of the rivaroxaban concentration (R2 = 0.72; 
P <0.0001). By the analysis of covariance, after 
adjustment for age, sex, renal function, and time 
to sampling there was no difference in rivaroxa‑
ban concentrations between DVT patients with 
thrombus progression and those with minor hem‑
orrhagic complications (F = 0.34, df = 1, P = 0.59).
Discussion The current study describes the first 
Polish experience with the measurements of riva‑
roxaban concentrations in everyday practice. We 
observed that, in DVT patients, plasma rivaroxa‑
ban concentrations estimated using the anti‑Xa 
assay did not differ between patients who report‑
ed thrombus progression or minor hemorrhag‑
ic complications, who were maintained on rivar‑
oxaban therapy. Our results suggest that the as‑
sociation between thrombotic or bleeding events 
and insufficient or markedly elevated plasma ri‑
varoxaban concentrations might not be obvious. 
One may speculate that poor compliance is crucial 
for the anticoagulant effects of rivaroxaban, while 
easy bruising and other mucocutaneous bleedings 
reported by many older patients on anticoagula‑
tion (which do not lead to drug withdrawal) are 
commonly unrelated to the accumulation of rivar‑
oxaban. We confirmed that the time since the last 
dose of the drug to blood sampling is a major de‑
terminant of the plasma rivaroxaban concentra‑
tion.4‑6 It should be highlighted that the self‑re‑
ported bleeding complications observed during 
treatment with rivaroxaban might be associated 
with the use of the out‑of‑counter anti‑inflamma‑
tory medications with antiplatelet actions, who 
were not reported by patients.
We confirmed that plasma rivaroxaban con‑
centrations are associated with PT. However, PT 
does not allow to quantitatively assess the anti‑
coagulant effect of rivaroxaban.8‑10 Moreover, our 
findings indicate that the measurements of riva‑
roxaban concentrations are of limited value in 
everyday practice and should be performed only 
under specific clinical circumstances, eg, in pa‑
tients with severe bleeding or requiring urgent 
invasive treatment.8‑10
In conclusion, we found that plasma rivarox‑
aban concentrations in patients with DVT may 
not be helpful in discriminating subjects who de‑
veloped thrombosis progression or minor hem‑
orrhagic complications on rivaroxaban. Patients 
with a history of such complications and mea‑
surements of rivaroxaban levels should be eval‑
uated with caution given the lack of the thera‑
peutic range for the results of the anti‑Xa assay 
in subjects receiving this anticoagulant. The mea‑
surable levels of rivaroxaban detected in a few 
control subjects deserve consideration suggest‑
ing that anti‑Xa assays could show falsely elevat‑
ed levels of the drug and standardization of those 
assays is urgently needed. Moreover, addition‑
al factors other than high levels of rivaroxaban 
